Table 2 |
||||||
|
Two phase III studies investigating the role of adding oxaliplatin to preoperative chemoradiotherapy in rectal cancer |
||||||
|
Study |
Schema |
N |
Grade 3/4 toxicities (%) |
LAR |
pCR |
Pathological metastatic disease (%) |
|
|
||||||
|
STAR-01 |
Radiotherapy (59.4 Gy) and 5-fluorouracil |
379 |
8% |
72% |
16% |
3% |
|
(primary objective: |
|
|||||
|
overall survival) |
Radiotherapy, 5-fluorouracil and oxaliplatin |
368 |
24% (p < 0.0001) |
73% |
16% |
0.5% |
|
|
||||||
|
ACCORD 12/0405 |
Radiotherapy (45 Gy) and capecitabine |
299 |
11% |
73% |
14% |
4% |
|
PRODIGE 2 (primary |
|
|||||
|
objective: pCR) |
Radiotherapy, capecitabine and oxaliplatin |
299 |
25% (p < 0.0001) |
76% |
19% |
3% |
|
|
||||||
|
N: patient number; LAR: low anterior resection; pCR: pathological complete response |
||||||
|
Javle and Hsueh Journal of Hematology & Oncology 2010 3:11 doi:10.1186/1756-8722-3-11 |
||||||
